Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)
China flag China · Delayed Price · Currency is CNY
5.25
-0.19 (-3.49%)
Sep 10, 2026, 12:44 PM CST

SHE:300039 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
782.3980.71593.31601.94694.691,345
Short-Term Investments
-553.39924.87--58.32
Trading Asset Securities
229.9958.53180.02150.01136.0751.26
Cash & Short-Term Investments
1,0121,5931,698751.95830.761,455
Cash Growth
-46.67%-6.22%125.84%-9.49%-42.88%-0.23%
Accounts Receivable
337.26409.79471.99529.32530.33567.99
Other Receivables
4.5620.4434.5110.3435.7746.77
Receivables
341.82430.22506.51539.67566.09614.76
Inventory
215.12200.41187.85171.79160.8165.14
Other Current Assets
281.3114.8222.8111.4716.7719.99
Total Current Assets
1,8512,2382,4151,4751,5742,254
Property, Plant & Equipment
267.67280.52267.85290.09304.66307.78
Long-Term Investments
1,0182,0701,6242,7301,312711.06
Goodwill
----9.0413.79
Other Intangible Assets
160.97163.57168.845.1144.2342.9
Long-Term Deferred Tax Assets
21.3321.4729.4431.6118.2615.1
Long-Term Deferred Charges
3.642.662.440.210.32-
Other Long-Term Assets
1,2721.7311.037.64996.4910.75
Total Assets
4,5944,7784,5184,5804,2593,356

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
92.8493.6199.37134.8591.0175.02
Accrued Expenses
0.819.7826.4623.2729.6915.92
Short-Term Debt
5.414.085.42---
Current Income Taxes Payable
18.5920.4631.6241.0835.543.47
Current Unearned Revenue
12.8812.4918.2945.6940.042.88
Other Current Liabilities
816.551.1589.9699.6793.39
Total Current Liabilities
138.51166.91232.3334.85295.96190.68
Long-Term Unearned Revenue
45.0544.2648.0343.2639.5147.16
Long-Term Deferred Tax Liabilities
125.38148.47135.11168.71162.7773.06
Total Liabilities
308.94359.64415.45546.82498.24310.9

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
1,0461,0461,0461,0461,0461,046
Additional Paid-In Capital
8.628.628.628.628.628.62
Retained Earnings
2,5462,5482,3232,0501,7851,577
Comprehensive Income & Other
684.59815.43724.5926.33921.98413.53
Total Common Equity
4,2854,4184,1024,0313,7623,045
Minority Interest
0.180.390.971.64-0.72-0
Shareholders' Equity
4,2854,4194,1034,0333,7613,045
Total Liabilities & Equity
4,5944,7784,5184,5804,2593,356

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
5.414.085.42---
Net Cash (Debt)
1,0071,5891,693751.95830.761,455
Net Cash Growth
-46.80%-6.16%125.12%-9.49%-42.88%2.28%
Net Cash Per Share
0.961.521.620.720.791.39
Filing Date Shares Outstanding
1,0451,0461,0461,0461,0461,046
Total Common Shares Outstanding
1,0451,0461,0461,0461,0461,046
Working Capital
1,7122,0712,1831,1401,2782,064
Book Value Per Share
4.104.223.923.853.602.91
Tangible Book Value
4,1244,2553,9333,9863,7082,988
Tangible Book Value Per Share
3.954.073.763.813.552.86
Buildings
-387.56386.31383.04372.25342.91
Machinery
-428.88425.35441.06427.9407.9
Construction In Progress
-241.230.526.1834.15